Health and Medicine
Oct. 29, 2020—An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.
Oct. 29, 2020—Histamine — commonly associated with allergies — also has a signaling role in the brain’s reward center and may offer a novel target for treating addiction.
Oct. 29, 2020—Vanderbilt epidemiologists identified new markers for colorectal cancer risk and characterized a previously unidentified tumor suppressor that regulates overall tumor volume in vivo.
Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.
Oct. 22, 2020—Vanderbilt Genetics Institute investigators have added a new method to the computational genetics toolbox. Their approach, described in the journal Nature Genetics, integrates vast genomics datasets to predict gene expression and facilitate discovery of genetic mechanisms underlying human diseases.
Oct. 20, 2020—A new method that keeps microbes and gut cells together will be useful for studies of complex host-microbe interactions and for analysis of clinical specimens.
Oct. 19, 2020—Older depressed adults show accelerated brain aging, according to a new study from Vanderbilt researchers, who suggest that the effects of depression may speed the decline in cognitive functions in older individuals.
Oct. 15, 2020—It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.
Oct. 15, 2020—Researchers at Vanderbilt University Medical Center have identified a key factor that coordinates the body’s repair response to severe injury in the stomach caused, most commonly, by infection by the bacterium Helicobacter pylori.
Oct. 15, 2020—The brain’s response to low oxygen — growth and remodeling of blood vessels — involves certain cell types and molecular pathways, Vanderbilt researchers have discovered.
COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
Oct. 8, 2020—A computer-based method developed at Vanderbilt University Medical Center that scans electronic medical records (EMRs) for genetic contributors to disease has been used for the first time to reveal the impact of race on health.